GLP-1 weight loss drugs containing the active ingredient semaglutide were originally intended to manage Type 2 Diabetes
In proglucagon gene ( Gcg ) knockout mice, the GLP-1 receptor antagonist, exendin 9-39, led to impaired glucose tolerance when Gcg was reactivated in the pancreas, but not when intestinal Gcg was reactivated (115)
Important safety information : Semaglutide has a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
The higher the dose of the GLP-1 agonist, the greater its effects
In certain cases, some people might find microdosing a helpful way to avoid unwanted side effects of GLP-1s or save some money
Common side effects include: Nausea and vomiting Digestive issues like diarrhoea, constipation, or abdominal pain Headaches and fatigue Injection site reactions Serious but less common side effects: Pancreatitis Gallbladder problems Kidney problems Low blood sugar Most gastrointestinal side effects settle within the first month or two
